Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


Articles published in Oncol Rep

Retrieve available abstracts of 70 articles:
HTML format



Single Articles


    September 2020
  1. HUO W, Qi F, Wang K
    Long noncoding RNA BCYRN1 promotes prostate cancer progression via elevation of HDAC11.
    Oncol Rep. 2020;44:1233-1245.
    PubMed     Abstract available


  2. WANG F, Wang W, Lu L, Xie Y, et al
    MicroRNA165p regulates cell survival, cell cycle and apoptosis by targeting AKT3 in prostate cancer cells.
    Oncol Rep. 2020;44:1282-1292.
    PubMed     Abstract available


  3. MOHAMMED SALEEM YI, Selim MI
    MDM2 as a target for ellagic acidmediated suppression of prostate cancer cells in vitro.
    Oncol Rep. 2020;44:1255-1265.
    PubMed     Abstract available


    August 2020
  4. WANG H, Huang W, Yu X, Li W, et al
    [Corrigendum] Two prostate cancerassociated polymorphisms in the 3'UTR of IGF1R influences prostate cancer susceptibility by affecting miRNA binding.
    Oncol Rep. 2020;44:786.
    PubMed     Abstract available


    June 2020
  5. WANG Y, Pei X, Xu P, Tan Z, et al
    E2F7, regulated by miR30c, inhibits apoptosis and promotes cell cycle of prostate cancer cells.
    Oncol Rep. 2020 Jun 24. doi: 10.3892/or.2020.7659.
    PubMed     Abstract available


    May 2020
  6. LIN M, Bu C, He Q, Gu J, et al
    TAZ is overexpressed in prostate cancers and regulates the proliferation, migration and apoptosis of prostate cancer PC3 cells.
    Oncol Rep. 2020 May 19. doi: 10.3892/or.2020.7616.
    PubMed     Abstract available


    February 2020
  7. JIANG G, Liang X, Huang Y, Lan Z, et al
    p62 promotes proliferation, apoptosisresistance and invasion of prostate cancer cells through the Keap1/Nrf2/ARE axis.
    Oncol Rep. 2020 Feb 28. doi: 10.3892/or.2020.7527.
    PubMed     Abstract available


  8. PU J, Li T, Liu N, Luo C, et al
    PLCepsilon knockdown enhances the radiosensitivity of castrationresistant prostate cancer via the AR/PARP1/DNAPKcs axis.
    Oncol Rep. 2020 Feb 26. doi: 10.3892/or.2020.7520.
    PubMed     Abstract available


    January 2020
  9. KASAJIMA R, Yamaguchi R, Shimizu E, Tamada Y, et al
    Variant analysis of prostate cancer in Japanese patients and a new attempt to predict related biological pathways.
    Oncol Rep. 2020 Jan 27. doi: 10.3892/or.2020.7481.
    PubMed     Abstract available


    December 2019
  10. LI W, Zhang J, Zou L, Cui J, et al
    Palmitoylome profiling indicates that androgens regulate the palmitoylation of alphatubulin in prostate cancerderived LNCaP cells and supernatants.
    Oncol Rep. 2019;42:2788-2796.
    PubMed     Abstract available


    November 2019
  11. QI JC, Xue WY, Zhang YP, Qu CB, et al
    Cholinergic alpha5 nicotinic receptor is involved in the proliferation and invasion of human prostate cancer cells.
    Oncol Rep. 2019 Nov 20. doi: 10.3892/or.2019.7411.
    PubMed     Abstract available


  12. HU R, Lu Z
    Long noncoding RNA HCP5 promotes prostate cancer cell proliferation by acting as the sponge of miR4656 to modulate CEMIP expression.
    Oncol Rep. 2019 Nov 8. doi: 10.3892/or.2019.7404.
    PubMed     Abstract available


    September 2019
  13. RAY J, Hoey C, Huang X, Jeon J, et al
    MicroRNA198 suppresses prostate tumorigenesis by targeting MIB1.
    Oncol Rep. 2019;42:1047-1056.
    PubMed     Abstract available


    July 2019
  14. TANG C, Liu T, Wang K, Wang X, et al
    Transcriptional regulation of FoxM1 by HIF1alpha mediates hypoxiainduced EMT in prostate cancer.
    Oncol Rep. 2019 Jul 25. doi: 10.3892/or.2019.7248.
    PubMed     Abstract available


  15. LING XH, Fu H, Chen ZY, Lu JM, et al
    miR505 suppresses prostate cancer progression by targeting NRCAM.
    Oncol Rep. 2019 Jul 11. doi: 10.3892/or.2019.7231.
    PubMed     Abstract available


  16. KAMINSKA K, Bialkowska A, Kowalewski J, Huang S, et al
    Differential gene methylation patterns in cancerous and noncancerous cells.
    Oncol Rep. 2019;42:43-54.
    PubMed     Abstract available


  17. MARTINS CA, Rocha GDG, Gattass CR, Takiya CM, et al
    Pomolic acid exhibits anticancer potential against a docetaxelresistant PC3 prostate cell line.
    Oncol Rep. 2019;42:328-338.
    PubMed     Abstract available


    May 2019
  18. MURAMATSU H, Sumitomo M, Morinaga S, Kajikawa K, et al
    Targeting lactate dehydrogenaseA promotes docetaxelinduced cytotoxicity predominantly in castrationresistant prostate cancer cells.
    Oncol Rep. 2019 May 24. doi: 10.3892/or.2019.7171.
    PubMed     Abstract available


  19. XU SG, Yu JJ, Shi Q, Niu Q, et al
    Conditionally replicative adenovirus carrying shRNA targeting EZH2 inhibits prostate cancer growth and invasion.
    Oncol Rep. 2019 May 13. doi: 10.3892/or.2019.7157.
    PubMed     Abstract available


    April 2019
  20. ZHANG J, Wang J, Luan T, Zuo Y, et al
    Deubiquitinase USP9X regulates the invasion of prostate cancer cells by regulating the ERK pathway and mitochondrial dynamics.
    Oncol Rep. 2019 Apr 18. doi: 10.3892/or.2019.7131.
    PubMed     Abstract available


    March 2019
  21. SUN W, Li L, Du Z, Quan Z, et al
    Combination of phospholipase Cepsilon knockdown with GANT61 sensitizes castrationresistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
    Oncol Rep. 2019 Mar 7. doi: 10.3892/or.2019.7054.
    PubMed     Abstract available


    January 2019
  22. ZHANG N, Su P, Li X, Xi J, et al
    Downregulated Kruppellike factor 4 expression is associated with the aggressiveness of prostate cancer.
    Oncol Rep. 2019 Jan 22. doi: 10.3892/or.2019.6975.
    PubMed     Abstract available


    December 2018
  23. LIAO W, Liu J, Liu B, Huang X, et al
    JIB04 induces cell apoptosis via activation of the p53/Bcl2/caspase pathway in MHCC97H and HepG2 cells.
    Oncol Rep. 2018;40:3812-3820.
    PubMed     Abstract available


    November 2018
  24. KAWAN MA, Kyrou I, Ramanjaneya M, Williams K, et al
    Involvement of the glutamine RFamide peptide and its cognate receptor GPR103 in prostate cancer.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6893.
    PubMed     Abstract available


  25. YE J, Chu C, Chen M, Shi Z, et al
    TROAP regulates prostate cancer progression via the WNT3/survivin signalling pathways.
    Oncol Rep. 2018 Nov 9. doi: 10.3892/or.2018.6854.
    PubMed     Abstract available


  26. TAKAO A, Yoshikawa K, Karnan S, Ota A, et al
    Generation of PTENknockout (/) murine prostate cancer cells using the CRISPR/Cas9 system and comprehensive gene expression profiling.
    Oncol Rep. 2018;40:2455-2466.
    PubMed     Abstract available


  27. WU S, Huang J, Hui K, Yue Y, et al
    2'Hydroxyflavanone inhibits epithelialmesenchymal transition, and cell migration and invasion via suppression of the Wnt/betacatenin signaling pathway in prostate cancer.
    Oncol Rep. 2018;40:2836-2843.
    PubMed     Abstract available


    October 2018
  28. TANG Y, Wu B, Huang S, Peng X, et al
    Downregulation of miR5053p predicts poor bone metastasisfree survival in prostate cancer.
    Oncol Rep. 2018 Oct 25. doi: 10.3892/or.2018.6826.
    PubMed     Abstract available


  29. WANG H, Huang W, Yu X, Li W, et al
    Two prostate cancerassociated polymorphisms in the 3'UTR of IGF1R influences prostate cancer susceptibility by affecting miRNA binding.
    Oncol Rep. 2018 Oct 22. doi: 10.3892/or.2018.6810.
    PubMed     Abstract available


  30. NASSER MI, Han T, Adlat S, Tian Y, et al
    Inhibitory effects of Schisandrin B on human prostate cancer cells.
    Oncol Rep. 2018 Oct 15. doi: 10.3892/or.2018.6791.
    PubMed     Abstract available


  31. MITRAN B, Andersson KG, Lindstrom E, Garousi J, et al
    Affibodymediated imaging of EGFR expression in prostate cancer using radiocobaltlabeled DOTAZEGFR:2377.
    Oncol Rep. 2018 Oct 15. doi: 10.3892/or.2018.6792.
    PubMed     Abstract available


  32. GAN BL, Zhang LJ, Gao L, Ma FC, et al
    Downregulation of miR2245p in prostate cancer and its relevant molecular mechanism via TCGA, GEO database and in silico analyses.
    Oncol Rep. 2018 Oct 3. doi: 10.3892/or.2018.6766.
    PubMed     Abstract available


  33. ZHANG P, Li Y, Tang X, Guo R, et al
    Zinc enhances chemosensitivity to paclitaxel in PC3 prostate cancer cells.
    Oncol Rep. 2018;40:2269-2277.
    PubMed     Abstract available


  34. DONG Q, Lv C, Zhang G, Yu Z, et al
    Impact of RNAbinding motif 3 expression on the whole transcriptome of prostate cancer cells: An RNA sequencing study.
    Oncol Rep. 2018;40:2307-2315.
    PubMed     Abstract available


  35. ULLAH K, Addai Peprah F, Yu F, Shi H, et al
    The application of prostate specific membrane antigen in CARTcell therapy for treatment of prostate carcinoma (Review).
    Oncol Rep. 2018 Oct 1. doi: 10.3892/or.2018.6758.
    PubMed     Abstract available


    August 2018
  36. WANG J, Yang X, Li R, Wang L, et al
    Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184/c-Myc axis.
    Oncol Rep. 2018 Aug 20. doi: 10.3892/or.2018.6661.
    PubMed     Abstract available


  37. DIAO X, Chen X, Pi Y, Zhang Y, et al
    Androgen receptor induces EPHA3 expression by interacting with transcription factor SP1.
    Oncol Rep. 2018;40:1174-1184.
    PubMed     Abstract available


    July 2018
  38. LIN JZ, Hameed I, Xu Z, Yu Y, et al
    Efficacy of gefitinibcelecoxib combination therapy in docetaxelresistant prostate cancer.
    Oncol Rep. 2018 Jul 24. doi: 10.3892/or.2018.6595.
    PubMed     Abstract available


    June 2018
  39. XU M, Jaing H, Wang H, Liu J, et al
    SB225002 inhibits prostate cancer invasion and attenuates the expression of BSP, OPN and MMP2.
    Oncol Rep. 2018 Jun 18. doi: 10.3892/or.2018.6504.
    PubMed     Abstract available


  40. KOU R, Zhao J, Gogoi P, Carskadon S, et al
    Enrichment and mutation detection of circulating tumor cells from blood samples.
    Oncol Rep. 2018;39:2537-2544.
    PubMed     Abstract available


    May 2018
  41. TANG Q, Ma J, Sun J, Yang L, et al
    Genistein and AG1024 synergistically increase the radiosensitivity of prostate cancer cells.
    Oncol Rep. 2018 May 30. doi: 10.3892/or.2018.6468.
    PubMed     Abstract available


    April 2018
  42. LIU Z, Zhang H, Ding S, Qi S, et al
    betaKlotho inhibits androgen/androgen receptorassociated epithelialmesenchymal transition in prostate cancer through inactivation of ERK1/2 signaling.
    Oncol Rep. 2018 Apr 25. doi: 10.3892/or.2018.6399.
    PubMed     Abstract available


  43. YANG A, Zhao Y, Wang Y, Zha X, et al
    Huaier suppresses proliferative and metastatic potential of prostate cancer PC3 cells via downregulation of Lamin B1 and induction of autophagy.
    Oncol Rep. 2018 Apr 5. doi: 10.3892/or.2018.6358.
    PubMed     Abstract available


    March 2018
  44. CHEN Q, Zhu L, Zong H, Song X, et al
    Subcellular localization of aquaporin 3 in prostate cancer is regulated by RalA.
    Oncol Rep. 2018 Mar 9. doi: 10.3892/or.2018.6308.
    PubMed     Abstract available


  45. XU S, Ge J, Zhang Z, Zhou W, et al
    miR-141 inhibits prostatic cancer cell proliferation and migration, and induces cell apoptosis via targeting of RUNX1.
    Oncol Rep. 2018;39:1454-1460.
    PubMed     Abstract available


    January 2018
  46. CAI C, He H, Duan X, Wu W, et al
    miR-195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression.
    Oncol Rep. 2018 Jan 31. doi: 10.3892/or.2018.6240.
    PubMed     Abstract available


  47. LAI Y, Kong Z, Zeng T, Xu S, et al
    PARP1-siRNA suppresses human prostate cancer cell growth and progression.
    Oncol Rep. 2018 Jan 26. doi: 10.3892/or.2018.6238.
    PubMed     Abstract available


    November 2017
  48. LIU T, Qiu X, Zhao X, Yang R, et al
    Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer.
    Oncol Rep. 2017 Nov 29. doi: 10.3892/or.2017.6121.
    PubMed     Abstract available


  49. WA Q, Li L, Lin H, Peng X, et al
    Downregulation of miR19a3p promotes invasion, migration and bone metastasis via activating TGFbeta signaling in prostate cancer.
    Oncol Rep. 2017 Nov 13. doi: 10.3892/or.2017.6096.
    PubMed     Abstract available


  50. KUBO M, Satoh T, Ishiyama H, Tabata KI, et al
    Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy.
    Oncol Rep. 2017 Nov 13. doi: 10.3892/or.2017.6095.
    PubMed     Abstract available


  51. ZOU P, Yang Y, Xu X, Liu B, et al
    Silencing of vacuolar ATPase c subunit ATP6V0C inhibits the invasion of prostate cancer cells through a LASS2/TMSG1-independent manner.
    Oncol Rep. 2017 Nov 10. doi: 10.3892/or.2017.6092.
    PubMed     Abstract available


  52. SZYSZKA M, Tyczewska M, Milecka P, Jopek K, et al
    Effects of leptin on leptin receptor isoform expression and proliferative activity in human normal prostate and prostate cancer cell lines.
    Oncol Rep. 2017 Nov 1. doi: 10.3892/or.2017.6066.
    PubMed     Abstract available


    October 2017
  53. KOU B, Liu W, Zhao W, Duan P, et al
    Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-beta/Smad2/3 signaling pathway.
    Oncol Rep. 2017 Oct 2. doi: 10.3892/or.2017.6012.
    PubMed     Abstract available


    September 2017
  54. NOWACKA-ZAWISZA M, Wisnik E
    DNA methylation and histone modifications as epigenetic regulation in prostate cancer (Review).
    Oncol Rep. 2017 Sep 20. doi: 10.3892/or.2017.5972.
    PubMed     Abstract available


  55. ZHOU Y, Gu P, Li J, Li F, et al
    Suppression of STIM1 inhibits the migration and invasion of human prostate cancer cells and is associated with PI3K/Akt signaling inactivation.
    Oncol Rep. 2017 Sep 18. doi: 10.3892/or.2017.5961.
    PubMed     Abstract available


  56. LING Z, Liu D, Zhang G, Liang Q, et al
    miR-361-5p modulates metabolism and autophagy via the Sp1-mediated regulation of PKM2 in prostate cancer.
    Oncol Rep. 2017;38:1621-1628.
    PubMed     Abstract available


    August 2017
  57. KHURANA N, Kim H, Chandra PK, Talwar S, et al
    Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
    Oncol Rep. 2017 Aug 30. doi: 10.3892/or.2017.5932.
    PubMed     Abstract available


    July 2017
  58. GAO C, Zhou Y, Jiang Z, Zhao Y, et al
    Cytotoxic and chemosensitization effects of Scutellarin from traditional Chinese herb Scutellaria altissima L. in human prostate cancer cells.
    Oncol Rep. 2017 Jul 24. doi: 10.3892/or.2017.5850.
    PubMed     Abstract available


  59. ZHOU Y, Ji Z, Yan W, Zhou Z, et al
    The biological functions and mechanism of miR212 in prostate cancer proliferation, migration and invasion via targeting Engrailed-2.
    Oncol Rep. 2017 Jul 12. doi: 10.3892/or.2017.5805.
    PubMed     Abstract available


    June 2017
  60. ZHOU Y, Ji Z, Yan W, Zhou Z, et al
    Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.
    Oncol Rep. 2017 Jun 29. doi: 10.3892/or.2017.5768.
    PubMed     Abstract available


  61. XUAN Q, Zhong X, Li W, Mo Z, et al
    CtBP2 is associated with angiogenesis and regulates the apoptosis of prostate cancer cells.
    Oncol Rep. 2017 Jun 28. doi: 10.3892/or.2017.5763.
    PubMed     Abstract available


    May 2017
  62. HATA S, Nomura T, Iwasaki K, Sato R, et al
    Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer.
    Oncol Rep. 2017 May 24. doi: 10.3892/or.2017.5669.
    PubMed     Abstract available


  63. LIU L, Lou N, Li X, Xu G, et al
    Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Oncol Rep. 2017 May 4. doi: 10.3892/or.2017.5623.
    PubMed     Abstract available


  64. BAI S, Chen T, Yu X, Luo M, et al
    The specific killing effect of matrine on castration-resistant prostate cancer cells by targeting the Akt/FoxO3a signaling pathway.
    Oncol Rep. 2017;37:2819-2828.
    PubMed     Abstract available


    April 2017
  65. YIN B, Liu Z, Wang Y, Wang X, et al
    RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells.
    Oncol Rep. 2017 Apr 19. doi: 10.3892/or.2017.5585.
    PubMed     Abstract available


    March 2017
  66. ZHAO Y, Yan M, Yun Y, Zhang J, et al
    MicroRNA-455-3p functions as a tumor suppressor by targeting eIF4E in prostate cancer.
    Oncol Rep. 2017 Mar 13. doi: 10.3892/or.2017.5502.
    PubMed     Abstract available


  67. BAI Y, Xiao Y, Dai Y, Chen X, et al
    Stanniocalcin 1 promotes cell proliferation via cyclin E1/cyclindependent kinase 2 in human prostate carcinoma.
    Oncol Rep. 2017 Mar 13. doi: 10.3892/or.2017.5501.
    PubMed     Abstract available


  68. ZHANG H, Du X, Sun TT, Wang CL, et al
    Lectin PCL inhibits the Warburg effect of PC3 cells by combining with EGFR and inhibiting HK2.
    Oncol Rep. 2017;37:1765-1771.
    PubMed     Abstract available


    February 2017
  69. KONG Q, Chen XS, Tian T, Xia XY, et al
    MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein.
    Oncol Rep. 2017;37:803-812.
    PubMed     Abstract available


    January 2017
  70. SUN W, Guo L, Shao G, Liu X, et al
    Suppression of LASP-1 attenuates the carcinogenesis of prostatic cancer cell lines: Key role of the NF-kappaB pathway.
    Oncol Rep. 2017;37:341-347.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: